Key facts
- This page summarizes Patrick J. Heron's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Sep 2024, 17:04.
Patrick J. Heron - 06 Sep 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- Director
- Issuer ticker
- MIRM
- Reported as of
- 06 Sep 2024
- Net transaction value
- +$9,563
- SEC form
- 4
- Accepted by SEC
- 10 Sep 2024, 17:04:14 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steve R. Bailey, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick J. Heron filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 10 Sep 2024.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: +$9,563.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRM
transaction
Common Stock
Purchase
- Transaction value
- $9,563
- Shares
- +230
- Change %
- +0.14%
- Price
- $41.58
- Shares after
- 162,193
- Date
- 06 Sep 2024
- Ownership
- By Frazier Life Sciences X, L.P.
- Footnotes
- F1, F2
MIRM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,566,912
- Date
- 06 Sep 2024
- Ownership
- By Frazier Life Sciences IX, L.P.
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.50 to $41.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
Footnote F2
The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
Footnote F3
The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.